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doi:10.1016/j.jmii.2011.12.026A skewed T-helper (Th)1/Th2 immune response is considered to be the major cause of allergic
disorders. Overproduction of Th2 cytokines, which promote recruitment and activation of mast
cells and eosinophils, plays a key part in the pathogenesis of allergic asthma. The mechanisms
by which omalizumab is effective in asthma treatment are not yet fully understood. A 16-year-
old girl who was experiencing frequent asthma attacks in spite of daily administration of
budesonide (640 mg) and montelukast (10 mg) was given omalizumab (375 mg) at intervals of
2 weeks, to prevent a visit to the emergency room. Plasma levels of Th1 cytokines [interferon
(IFN)-g and interleukin (IL)-12p70], Th2 cytokines (IL-4 and IL-13), other proinflammatory and
regulatory cytokines [IL-6, IL-10, IL-17, tumor necrosis factor (TNF)-a, and transforming growth
factor (TGF)-b], chemokines [monocyte chemotactic protein (MCP)-1, chemokine ligand (CCL)
7, and CCL17], and soluble Fas ligand (sFasL) were measured before treatment and after treat-
ment for 8 weeks. She showed a good clinical response to omalizumab: her lung function
parameters improved and the use of b2-agonist decreased. No emergency room visits were
required after omalizumab treatment for 8 weeks. Plasma levels of sFasL and TGF-b showed
obvious increases after omalizumab therapy. IL-12p70 levels were decreased as compared to
the corresponding baseline levels. These findings suggest that the effects of omalizumab in
asthma treatment are not restricted to the regulation of the skewed Th1/Th2 cytokine immuneChildren’s Hospital, 123 Ta-Pei Road, Niao-Sung Hsiang, Kaohsiung Hsien 833, Taiwan.
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70 S.-L. Kao et al.response, and sFasL-mediated apoptosis and regulatory T-cell (Treg)-mediated TGF-b seem to
have important roles in the therapeutic effects of omalizumab.
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Skewed T-helper (Th)1/Th2 immune response is the major
factor responsible for allergic disorders. Overproduction of
Th2 cytokines, which promote recruitment and activation of
mast cells and eosinophils, plays a key part in the patho-
genesis of allergic disorders. Asthma is defined as a chronic
airway inflammation mediated by Th2 immune response and
eosinophils. Inhaled corticosteroids (ICSs) are the major
medication for asthma control. The other options for
asthma control include leukotriene modifiers, theophylline,
and long-acting b2-agonists.
Omalizumab, a recombinant monoclonal anti-
immunoglobulin (Ig)E antibody (Ab), has proven efficacy
in the treatment of allergic diseases. This drug is usually
administered to patients with moderate-to-severe persis-
tent allergic asthma that is inadequately controlled by
treatment with medium- to high-dose ICSs and other
controller medications. In addition to being used for the
treatment of asthma, omalizumab is also effective for the
treatment of allergic rhinitis and atopic dermatitis.1 The
mechanisms by which omalizumab is effective in asthma
treatment are not yet fully understood.
We present here the case of 16-year-old girl in whom
omalizumab treatment was administered because of
frequent asthma acute attacks necessitating emergency
room visits. Plasma levels of Th1/Th2/Th3 cytokines, che-
mokine, and soluble Fas ligand (sFasL) were measured. On
the basis of our observations, we suggest a new therapeutic
mechanism for omalizumab.Table 1 Changes in leukocyte subpopulations and IgE due
to omalizumab treatment
Pre-Tx 1 month
WBC (/mm3) 9700 8100
Eosinophils (/mm3) (%) 281 (2.9%) 121 (1.5%)
CD3 (/mm3) (%) 1605 (64%) 1186 (67%)
CD4 (/mm3) (%) 818 (33%) 674 (38%)
CD8 (/mm3) (%) 650 (26%) 435 (25%)
CD19 (/mm3) (%) 444 (18%) 347 (20%)
Total IgE (KU/L) 599 1202
WBC: white blood cells; IgE: immunoglobulin E.Case report
A 16-year-old girl developed respiratory allergies to house
dust mite and showed symptoms of seasonal rhinitis and
asthma. Despite receiving treatment with high doses of
inhaled corticosteroids (budesonide, 640 mg/day) in
combination with long-acting b2-agonist and leukotriene
modifier (montelukast, 10 mg/day), the patient’s asthma
remained poorly controlled. Repeated episodes of severe
asthma (more than five visits to the emergency department
per month) necessitated discontinuation of the patient’s
school education. For the treatment of these repeated
episodes, the patient received omalizumab 375 mg at
intervals of 2 weeks. The patient’s asthma symptom score
and b2-agonist use were documented daily in diaries, and
spirometry was performed at each visit. The differential
peripheral leukocyte count and T-cell subsets were
measured (Table 1). Plasma levels of Th1 cytokines (IFN-g
and IL-12p70), Th2 cytokines (IL-4 and IL-13), other proin-
flammatory and regulatory cytokines (IL-6, IL-10, IL-17,
TNF-a, and TGF-b), chemokines (MCP-1, CCL7, and CCL17),and sFasL were also measured every month (Table 2). After
3 months of omalizumab treatment, it was possible to
reduce the patient’s long-term treatment could to bude-
sonide 320 mg/day. She showed clinical improvement,
which was evident by the absence of emergency depart-
ment visits for severe attacks and a decrease in rhinitis
symptoms. The respiratory function parameters of forced
expiratory volume in 1 s (FEV1) and forced vital capacity
(FVC) also improved from 43.5% to 54.4% and from 36.8% to
41.5%, respectively, of the predicted values. After omali-
zumab treatment, the girl was able to resume school
attendance. The omalizumab treatment was stopped
because of problems with health insurance. However, we
found that the levels of sFasL and TGF-b dramatically
increased but those of IL-12p70 decreased. The changes in
the levels of other cytokines and chemokines were not
prominent.
Discussion
The inflammatory properties of asthma have been well
studied. IgE activates a variety of inflammatory cells,
including mast cells and basophils, through interactions
with receptors (Fc 3RI and Fc 3RII). The activation of mast
cells by IgE and the resulting mediator release is the first
step in the allergic inflammatory cascade. Proinflammatory
mediators (such as prostaglandin D2, leukotriene C4, TNF-
a, and a variety of Th2-type cytokines, chemokines, and
growth factors) released from activated mast cells are
responsible for the initial symptoms of asthma and stimu-
late dendritic cells and additional Th2-related inflammatory
reactions.2,3 The central role of IgE in allergic inflammatory
asthma provided the rationale for the development of
omalizumab.4,5
Omalizumab can bind to the constant region of the IgE
molecule, thereby preventing the interaction of IgE with
IgE receptors on inflammatory cells and decreasing
inflammatory cell activation. Omalizumab can decrease the
Table 2 Changes in cytokine and chemokine levels due to
omalizumab treatment
Pre-Tx 1 month 2 months
FasL (pg/ml) 58.5 6.56 103.5
Th1 cytokines
IL-12p70 (pg/ml) 3.51 0.06 0
IFN-g (pg/ml) 13.72 13.08 13.39
IFN-a (pg/ml) 57.84 80.49 45.96
Th2 cytokines
IL-4 (pg/ml) 93.98 97.49 94.94
IL-13 (pg/ml) 10.68 10.98 11.4
Pro-inflammatory and other regulatory cytokines
IL-6 (pg/ml) 0 0 0
IL-8 (pg/ml) 8.82 0 61.06
TNF-a (pg/ml) 14.81 15.14 12.90
TGF-b1 (pg/ml) 617.2 1752.8 14768
IL-17 (pg/ml) 10.18 9.43 9.54
Chemokines
CCL17 (pg/ml) 19.63 5.75 17.54
MCP-1 (pg/ml) 322.27 340.19 163.3
MCP-3 (pg/ml) 32.35 34.11 32.79
FasL: Fas ligand; Th: T helper; IL: interleukin; IFN: interferon;
TNF: tumor necrosis factor; TGF: transforming growth factor;
CCL: chemokine ligand; MCP: monocyte chemotactic protein.
Mechanism of omalizumab treatment for asthma 71circulating levels of unbound IgE but not those of total
IgE.6,7 Reductions in the circulating level of IgE leads to
further reductions in Fc 3RI expression on mast cells, baso-
phils, and dendritic cells.6 Omalizumab can reduce the
eosinophil count in sputum and bronchial biopsies8,9 and
can suppress Th2 immune response by reducing the number
of IL-2þ and IL-13þ T lymphocytes and the circulating IL-5
and IL-13 levels4,10 without effecting the IFN-g concentra-
tion. In our patient, the total serum IgE level was increased
and the eosinophil count was decreased after omalizumab
therapy. However, instead of the IL-4 or IL-13 levels, the
plasma IL-12p70 levels were decreased after omalizumab
treatment. In contrast, the TGF-b levels were increased
after omalizumab treatment. Omalizumab may also
suppress some Th1 cytokines, presumably via the produc-
tion of the Treg mediator TGF-b.
Moreover, omalizumab has been reported to show
additional anti-inflammatory activity by inducing eosinophil
apoptosis through an unknown mechanism.9,11Further studies involving more patients cases and
a longer treatment period are needed to confirm our
observation. However, we found that the plasma sFasL
level showed an obvious increase after omalizumab treat-
ment. This might support a solution for the apoptosis and
decrease of eosinophils.
In conclusion, our finding suggests that in addition to
regulating the skewed balance of Th1/Th2 cytokines, oma-
lizumab has other effects in asthma treatment. The
apoptotic ligand sFasL and the Treg mediator TGF-b may
also be important mediators for the therapeutic effects of
omalizumab.References
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